Jagpal S Gosal, MD | |
1912 Nw Copper Oaks Cir, Blue Springs, MO 64015-8300 | |
(660) 829-3700 | |
(660) 829-3701 |
Full Name | Jagpal S Gosal |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 1912 Nw Copper Oaks Cir, Blue Springs, Missouri |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669457743 | NPI | - | NPPES |
209734532 | Medicaid | MO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 114329 (Missouri) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jagpal S Gosal, MD Po Box 116, Blue Springs, MO 64013 Ph: (660) 287-2956 | Jagpal S Gosal, MD 1912 Nw Copper Oaks Cir, Blue Springs, MO 64015-8300 Ph: (660) 829-3700 |
News Archive
This past year has been transformational in terms of not only a global pandemic but a sustained focus on racism and systemic injustice.
Estrogen and progesterone hormones in birth control do not influence the effectiveness of highly active antiretroviral therapy (HAART), which is used to treat HIV infection, according to researchers from the Johns Hopkins Bloomberg School of Public Health and other institutions. The study is published in the May 1, 2005, issue of the American Journal of Epidemiology.
Freezing of medical tissue and cells usually requires the addition of cryopreservatives, although the added compounds can have undesired effects in subsequent applications.
The off-label and untested use of drug-coated stents in the treatment of coronary artery blockage is common in U.S. practice, and ischemic complication rates are higher among patients receiving drug-coated stents for off-label indications, according to two studies in the May 9 issue of Journal of the American Medical Association.
Winston Laboratories, Inc. ("Winston Labs"), a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced that it has received a Notice of Non-compliance ("NON") from the Therapeutics Drug Directorate, Health Canada (the "Directorate") for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.
› Verified 3 days ago